Sandoz Group shares climbed after the Swiss drugmaker reported higher sales for the second quarter, driven by its biosimilar segment and a return to growth in generics. The company said net sales were $3.01 billion in the second quarter, up 7% compared with a year earlier when adjusting for currency changes. Analysts had forecast quarterly sales of $2.99 billion, according to consensus estimates provided by Vara Research.

Sales of biosimilar drugs jumped 22% at constant currency, while those of generic drugs were up 1%, recovering from a decline in the first quarter caused by headwinds in Sandoz’s anti-infective business. The stronger performance in the biosimilar segment helped offset challenges in other areas, supporting the company's outlook for continued growth.

Investors reacted positively, pushing Sandoz shares higher on the day of the earnings release. The company's ability to maintain momentum in both biosimilars and generics positions it well for future earnings growth. The Swiss drugmaker’s earnings beat further valuable signals for the broader generics market. Sandoz’s focus on expanding its biosimilar pipeline is expected to drive future revenue.